Last reviewed · How we verify
NCT04319172: COVIDSOT
Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients
trial in Transplant Recipient in 488 participants. Completed in 31 December 2023.
28 December 2022
Quick facts
| Lead sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 488 |
| Start date | 12 March 2020 |
| Primary completion | 28 December 2022 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Spain |
Conditions studied
- Transplant Recipient — all drugs for Transplant Recipient →
- Infections, Coronavirus — all drugs for Infections, Coronavirus →
Sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla — full company profile →
Who can join
16 and older, any sex, with Transplant Recipient or Infections, Coronavirus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall purpose of this project is to better understand the incidence, risk factors, etiology, clinical manifestations and outcome of tCOVID19 in solid organ transplant recipients. The results obtained will allow us to gain insight on the need of antiviral treatment, on the strategy for complications surveillance, on how to adjust the immunosuppressant therapy and on the level of care in which each patient should be treated. In order to attain the objectives previously described we will develop a multicenter prospective study of consecutive cases of COVID-19 among solid organ transplant recipients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
COVID-19 clinical phenotypes in vaccinated and nonvaccinated solid organ transplant recipients: a multicenter validation study.
Infante-Domínguez C, Salto-Alejandre S, Álvarez-Marín R, Sabé N, et al · · 2024 · cited 3× · PMID 39622951 · DOI 10.1038/s41598-024-81099-2 -
The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response.
Migo W, Boskovic M, Likic R. · · 2021 · cited 3× · PMID 34870159 · DOI 10.1016/j.crphar.2021.100064
Verify or expand the search:
- PubMed search for NCT04319172
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transplant Recipient
Currently open trials in the same condition.
- NCT05410496 — Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection · Phase 4 · active not recruiting
Other Fundación Pública Andaluza para la gestión de la Investigación en Sevilla trials
Trials by the same sponsor.
- NCT05225961 — ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem · Phase 4 · completed
- NCT07521969 — Out-patiente Management for Gangrenous Acute Appendicitis: The PENDI-CSI II Randomized Clinical Trial. · NA · recruiting
- NCT07153406 — Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients · Phase 3 · not yet recruiting
- NCT07353424 — A Multicenter Randomized Clinical Trial Compared With Standard Clinical Practice to Evaluate the Efficacy of a Polypheno · NA · recruiting
- NCT06602310 — Utility of Preanestes@s2.0, a Web Based Application for Preoperative Assessment. · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04319172 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- Last refreshed: 8 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04319172.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing